Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) stock is trading lower on Thursday. The company released patient updates on ...

Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") .  Such investors are advised to contact Danielle Peyton at ...

Nektar Therapeutics said that a phase 1 study examining a combination of NKTR-255 in combination with an autologous ...

Itovebi is supplied as a tablet in 2 dosage strengths: 3 mg and 9 mg. Patients should be selected for treatment based on the presence of 1 or more PIK3CA mutations in plasma specimens. The FDA has ...

Short-course induction chemotherapy prior to chemoradiotherapy should be considered a standard of care, according to ...

Nivolumab plus AVD “should be a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin’s lymphoma,” according to researchers.

Opdivo showed a 52% progression-free survival advantage over Adcetris in newly diagnosed Hodgkin’s lymphoma, according to a ...

Researchers investigated whether induction chemotherapy improves PFS and OS in patients with locally advanced cervical cancer ...

For patients with stage III or IV Hodgkin lymphoma, nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) yields ...

An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, ...

In mid-2023, the SWOG S1826 phase 3 trial in advanced Hodgkin lymphoma reported highly positive primary results earlier than expected, after the trial’s second planned interim analysis found the ...

The U.S. Food and Drug Administration has approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and ...